What is the P/E ratio of Glenmark Generics . - (Amalgamated)?

The latest standalone P/E ratio of Glenmark Generics . - (Amalgamated) as of 01-Jan-1970 is 0.00.

What is the P/B ratio of Glenmark Generics . - (Amalgamated)?

The latest standalone P/B ratio of Glenmark Generics . - (Amalgamated) as of 01-Jan-1970 is 0.00.

What is the 52-week high and low of Glenmark Generics . - (Amalgamated)?

The 52-week high of Glenmark Generics . - (Amalgamated) is Rs. and the 52-week low is Rs. .

Glenmark Generics Ltd. - (Amalgamated) - Stock Valuation and Financial Performance

Name: Glenmark Generics . - (Amalgamated)
Brand: Glenmark Generics . - (Amalgamated)

BSE: 0 | NSE: | Pharmaceuticals & Drugs | Small Cap

Place order

BSE Share Price
Not Listed

DeciZen - make an informed investing decision on Glenmark Generics

Based on:

Data

M-Cap below 100cr DeciZen not available

Glenmark Generics Ltd. - (Amalgamated) stock performance -

PE Chart Key Ratios

P/E Ratio (SA):

0.00

Market Cap:

0 Cr.

52-wk low:

52-wk high:

Is an attractive stock to invest in?

1. Is a good quality company?

Data is not available for this company.

2. Is undervalued or overvalued?

No data found

3. Is a good buy now?

No data found

10 Year X-Ray of Glenmark Generics:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	Mar'13	Mar'14	TTM
ROCE % ⓘ	-45.2%	-1.6%	-1.6%	-1%	49.2%	19.8%	13%	10.7%	21.6%	19.3%	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	0	0	0	0	781	826	1,069	1,283	1,726	1,896	1,896
Sales YoY Gr.	-	NA	NA	NA	NA	5.8%	29.4%	20%	34.6%	9.8%	-
Adj EPS ⓘ	-5.6	-0.2	-0.2	-0.1	19.2	10	13.8	12	28.9	26	26.2
YoY Gr.	-	NA	NA	NA	NA	-48.2%	38.4%	-12.6%	140%	-10.1%	-
BVPS (₹) ⓘ	12.4	12.2	12.2	9.9	23.8	69.9	72.6	87	112.8	138.6	139.9
Adj Net Profit ⓘ	0	0	0	-0.5	144	149	207	181	436	392	392
Cash Flow from Ops. ⓘ	0	0	0	-35.3	-198	187	489	46.9	525	838	-
Debt/CF from Ops. ⓘ	0	0	0	-0.6	-2.3	2.7	1.7	20	1	0	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	NA	19.4%	21%	9.8%
Adj EPS ⓘ	NA	6.3%	23.6%	-10.1%
BVPSⓘ	30.8%	42.2%	24%	22.9%
Share Price	-	-	-	-

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	Mar'13	Mar'14	TTM
Return on Equity % ⓘ	-45.2	-1.6	-1.6	-1.4	113.7	24.3	19.4	15.1	29	20.7	18.8
Op. Profit Mgn % ⓘ	0	0	0	0	31.1	32.4	26.8	22.1	32.7	29.1	NAN
Net Profit Mgn % ⓘ	0	0	0	0	18.4	18	19.3	14.1	25.3	20.7	20.7
Debt to Equity ⓘ	0	0	0	0.3	2.6	0.5	0.8	0.7	0.3	0	-
Working Cap Days ⓘ	0	0	0	0	212	435	477	455	325	288	0
Cash Conv. Cycle ⓘ	0	0	0	0	154	218	125	99	32	-33	0

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to %

Sales growth has been subdued in last 3 years %

Sales growth is not so good in last 4 quarters at %

Latest Financials - Glenmark Generics Ltd. - (Amalgamated)

	Standalone	Consolidated
TTM EPS (₹)	26.2	0
TTM Sales (₹ Cr.)	1,896	0
BVPS (₹.) ⓘ	139.9	10
Reserves (₹ Cr.) ⓘ	1,942	-
P/BV ⓘ	0.00	0.00
PE ⓘ	0.00	0.00

From the Market
52 Week Low / High (₹)	- / -
All Time Low / High (₹)	- / -
Market Cap (₹ Cr.)	0
Equity (₹ Cr.)	149.6
Face Value (₹)	10
Industry PE ⓘ	48.8

Management X-Ray of Glenmark Generics:

Shareholding Pattern

No Data To Display

Promoter's Holding & Share Pledging

Valuation of Glenmark Generics

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Glenmark Generics

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	Mar'13	Mar'14
Sales	0	0	0	0	781.03	826.18	1,068.83	1,282.50	1,726.13	1,895.60
Operating Expenses ⓘ	0.03	0	0	0.73	537.80	558.61	782.69	999.02	1,161.36	1,343.84
Manufacturing Costs	0	0	0	0	44.29	440.93	634.72	134.03	157.59	217.71
Material Costs	0	0	0	0	361.68	0	0	648.01	747.63	797.61
Employee Cost	0	0	0	0	33.38	0	0	91.63	112.22	144.69
Other Costs ⓘ	0.03	0	0	0.73	98.45	117.69	147.98	125.35	143.93	183.83
Operating Profit ⓘ	-0.03	0	0	-0.73	243.23	267.56	286.13	283.48	564.78	551.76
Operating Profit Margin (%)	-	-	-	-	31.1%	32.4%	26.8%	22.1%	32.7%	29.1%
Other Income ⓘ	0	0	0	0	83.69	27.14	49.97	72.21	45.23	39.30
Interest ⓘ	0	0	0	0.04	52.41	97.05	27.44	58.62	65.76	36.55
Depreciation ⓘ	0	0	0	0	21.19	26.84	32.64	38.78	40.71	46.37
Exceptional Items ⓘ	0	0	0	0	-111.11	0	-233.98	0	0	0
Profit Before Tax ⓘ	-0.03	0	0	-0.77	142.22	170.82	42.04	258.28	503.53	508.14
Tax ⓘ	0	0	0	-0.26	37.90	21.91	-0.67	39.95	49.59	115.72
Profit After Tax	-0.03	0	0	-0.51	104.31	148.91	42.71	218.33	453.94	392.42
PAT Margin (%)	-	-	-	-	13.4%	18.0%	4.0%	17.0%	26.3%	20.7%
Adjusted EPS (₹)	-5.6	-0.2	-0.2	-0.1	13.9	10.0	2.9	14.5	30.1	26.0
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	12%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	Mar'13	Mar'14
Equity and Liabilities
Shareholders Fund	0.06	0.06	0.06	74.50	178.81	1,045.91	1,088.98	1,307.68	1,700.91	2,093.55
Share Capital ⓘ	0.05	0.05	0.05	75	75	149.60	149.96	150.33	150.86	151.07
Reserves ⓘ	0.01	0.01	0.01	-0.50	103.81	896.31	939.02	1,157.36	1,550.06	1,942.47
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	0	0	0	20.35	460.31	505.55	827.26	935.64	529.25	0
Long Term Debt	0	0	0	20.35	460.31	505.55	827.26	470.28	470.28	0
Short Term Debt	0	0	0	0	0	0	0	465.37	58.97	0
Trade Payables	0	0	0	0	0	156.56	162.74	372.05	535.19	788.30
Others Liabilities ⓘ	0	0	0	-0.17	902.75	191.97	316.10	88.58	149.04	143.65
Total Liabilities ⓘ	0.06	0.06	0.06	94.68	1,541.87	1,900	2,395.07	2,703.95	2,914.39	3,025.51
Fixed Assets
Gross Block	0	0	0	0	605.40	443.25	512.22	582.30	663.99	948.87
Accumulated Depreciation	0	0	0	0	21.18	47.96	126.73	165.46	201.49	247.52
Net Fixed Assetsⓘ	0	0	0	0	584.22	395.28	385.49	416.84	462.50	701.35
CWIP ⓘ	0	0	0	0	0	289.57	186.66	220.31	290.43	135.42
Investmentsⓘ	0	0	0	57.82	83.15	106.16	106.16	529.74	529.74	529.74
Inventories	0	0	0	0	181.36	216.23	248.97	246.39	297.10	368.69
Trade Receivables	0	0	0	0	477.87	382.26	389.29	518.54	629.52	326.77
Cash Equivalents	0.06	0.06	0.06	1.95	3.07	12.91	18.98	21.50	44.56	223.55
Others Assetsⓘ	0	0	0	34.91	212.21	497.59	1,059.53	750.63	660.52	739.99
Total Assets ⓘ	0.06	0.06	0.06	94.68	1,541.87	1,900	2,395.07	2,703.95	2,914.39	3,025.51

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'05	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	Mar'13	Mar'14
Cash Flow From Operating Activity ⓘ	0	-35.27	-197.54	187.47	489.46	46.86	525.17	838.38
PBT ⓘ	-0.03	-0.77	142.22	170.82	42.04	258.28	503.53	508.14
Adjustment ⓘ	0.03	0.36	58.46	153	306.82	-24.05	80.82	54.66
Changes in Working Capital ⓘ	0	-34.86	-337.48	-102.02	141.86	-140.37	-25.02	411.61
Tax Paid ⓘ	0	0	-60.74	-34.32	-1.26	-47	-34.17	-136.02
Cash Flow From Investing Activity ⓘ	0	-1.82	-215.20	-140.94	-723.91	-114.65	16.80	-99.17
Capex	0	0	-116.27	-99.64	-43.80	-69.03	-74.77	-123.49
Net Investments	0	-1.82	-25.33	-23	0	0	0	0
Others ⓘ	0	0	-73.60	-18.30	-680.11	-45.62	91.57	24.32
Cash Flow From Financing Activityⓘ	0.05	38.80	413.86	-36.69	240.53	72.07	-518.78	-562.12
Net Proceeds from Shares ⓘ	0.05	36.95	0	0	0	0.37	0.53	0.22
Net Proceeds from Borrowing ⓘ	0	1.85	215.10	181.11	279.59	0	0	0
Interest Paid ⓘ	0	0	-26.10	-91.62	-71.24	-35.99	-48.70	-33.12
Dividend Paid ⓘ	0	0	0	0	0	0	-52.70	0
Others ⓘ	0	0	224.86	-126.18	32.17	107.69	-417.92	-529.21
Net Cash Flow ⓘ	0.05	1.71	1.12	9.84	6.08	4.28	23.18	177.10

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	Mar'13	Mar'14
Ratios
ROE (%)	-45.16	-1.63	-1.64	-1.36	82.36	24.32	4	18.22	30.18	20.68
ROCE (%)	-45.16	-1.63	-1.64	-1.53	53.03	24.46	4.01	15.24	25.45	25.2
Asset Turnover Ratio	0	0	0	0	0.95	0.48	0.5	0.51	0.62	0.64
PAT to CFO Conversion(x)	N/A	N/A	N/A	N/A	-1.89	1.26	11.46	0.21	1.16	2.14
Working Capital Days
Receivable Days	0	0	0	0	223	190	132	128	120	91
Inventory Days	0	0	0	0	85	88	79	70	57	64
Payable Days	0	0	0	0	0	0	0	151	221	303

Glenmark Generics Ltd. - (Amalgamated) Stock News

Glenmark Generics Ltd. - (Amalgamated) FAQs

What is the share price of Glenmark Generics?

Company share prices are keep on changing according to the market conditions. The closing price of Glenmark Generics on 01-Jan-1970 05:30 is ₹0.00.

What is the market cap of Glenmark Generics?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jan-1970 05:30 the market cap of Glenmark Generics stood at ₹0.00.

What is the P/E ratio of Glenmark Generics?

The latest P/E ratio of Glenmark Generics as of 01-Jan-1970 05:30 is 0.00.

What is the P/B ratio of Glenmark Generics?

The latest P/B ratio of Glenmark Generics as of 01-Jan-1970 05:30 is 0.00.

What is the 52-week high and low of Glenmark Generics?

The 52-week high of Glenmark Generics is ₹0.00 and the 52-week low is ₹0.00.

What is the TTM revenue of Glenmark Generics?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Glenmark Generics is ₹1,896 ( Cr.) .

About Glenmark Generics Ltd. - (Amalgamated)

Glenmark Generics was originally incorporated as Glenmark Organics on September 29, 1994. It is a subsidiary company of Glenmark Pharmaceuticals (GPL). The company received the certificate of commencement of business on September 12, 1996. The name was changed to Glenmark Generics on November 29, 2007. Consequential to this, a fresh certificate of incorporation was granted to the company on November 29, 2007.

Glenmark is a generic pharmaceutical company with research and development, marketing and distribution capabilities. It focuses on the development, manufacturing, marketing and distribution of generic finished dosage forms (FDFs) through wholesalers, distributors, retailers and other channels, including hospitals and through open tenders.

The company also develops, manufactures, markets and distributes active pharmaceutical ingredients (APIs) to other pharmaceutical companies. For certain products, the company manufactures the APIs used in its FDFs.

It has five manufacturing facilities in India, two of which have been inspected by the US Food and Drug Administration (USFDA) and the Medicines and Healthcare products Regulatory Agency (UK MHRA), and a new facility in Argentina.

Pursuant to a re-organization of the business, GPL transferred its generics business to the company with effect from April 1, 2008 by entering into a business transfer agreement dated December 24, 2008. Further, the company acquired its subsidiary Glenmark Generic Holdings S A by way of a share purchase agreement entered into between Glenmark Holding S A, Switzerland and Glenmark Generics Finance S A, Switzerland, a wholly-owned subsidiary of the Company.

Subsidiaries of the Company:

1. Glenmark Generics Finance S A, Switzerland

2. Glenmark Generics Holding S A, Switzerland

3. Glenmark Generics (Europe), UK

4. Glenmark Generics Inc, USA

5. Glenmark Generics S A, Argentina.

Products offered:

As of September 18, 2009, the company is authorized to distribute approximately 49 FDF products in the US markets, approximately 66 APIs globally and has around 41 Drug Master Files (DMFs) filed with the USFDA. The company's main FDF products are:

Oxcarbazepine (anti-convulsant)
Gabapentin (anti-convulsant)
Hydroxyzine (sedating antihistamine)
Naproxen (non-steroidal anti-inflammatory or NSAID)
Pravastatin Sodium (anti-lipemic)

Its main API products are:

Topiramate
Amiodarone
Telmistartan
Esomeprazole Magnesium
Lornoxicam
Linezolid
Perindopril Erbumine.

Key milestones:

December 24, 2007:- The company entered into a Business Transfer Agreement with GPL for transfer of the generics business.
July 4, 2008:- The Bombay High Court approved the scheme of amalgamation of G M Pharma with the company.
2011 -SCRIP, a leading global pharmaceutical and biotech news publication, honoured Glenmark with 'Best Company in an Emerging Marketsâ€™ & 'Best Overall Pipelineâ€™ titles, for the year 2011.
2010 -Glenmark was conferred the 'Indian Innovator Pharmaceutical Company of the Year' Award for the year 2010 by Frost and Sullivan.